Navigation Links
Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma
Date:2/17/2009

SEATTLE, Feb. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that updated safety and efficacy data from the phase III trial of pixantrone provides further support for a robust clinical benefit for pixantrone when used as single agent therapy in the treatment of multiple relapsed aggressive non-Hodgkin's lymphoma (NHL). On an intent-to-treat analysis, pixantrone recipients who achieved a complete remission did so during the first 2 cycles of therapy, compared to 4 cycles among standard chemotherapy recipients, (1.9 months vs. 3.6 months, pixantrone vs. standard chemotherapy). The duration of response in the patients was similar in the 37% of pixantrone patients who had either a partial or complete response compared to the 14% of comparator patients with a major response. However, the overall progression free survival (PFS) was significantly longer in the pixantrone arm (4.7 months vs. 2.6 months, hazard ratio = 0.6; p = 0.0074, pixantrone vs. standard chemotherapy). Thirty-two percent (32%) of pixantrone patients received all 6 cycles of therapy, with 84% receiving 5 of 6 cycles of treatment. Pixantrone recipients had a low incidence of severe neutropenia complicated by either fever or documented infections, or severe vomiting or diarrhea. Pixantrone patients also experienced a low incidence of hair loss, a very common side effect of other drugs in this class. Overall, the incidence of serious adverse events was similar between pixantrone and the control arm. The pixantrone patients had a higher incidence of leucopenia and neutropenia and numerically more severe cardiac events (4 vs 2) than in the control arm. Disease progression reported as an adverse event was less frequent in the pixantrone than in the control arm (1.5% vs. 13.4%).

"We were impressed to see that 84% of patients received at least 5 cycles of pixantrone therapy with a median total dose of 1,475 mg, despite
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
2. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
3. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
4. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
5. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
6. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
7. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
8. Nationwide Survey Shows Infertility Patients Prefer ENDOMETRIN(R) Compared With Other Progesterone Supplements
9. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
10. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
11. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... PINE BROOK, N.J. , Sept. 22, 2014 ... developing antibody therapies to treat infectious disease, today ... adult volunteer safety studies of obiltoxaximab (ETI-204). Obiltoxaximab ... of inhalational anthrax and data from these studies ... when administered intravenously (IV) at the intended therapeutic ...
(Date:9/22/2014)...  AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), ... machines, announced today that they are starting production of ... unit is designed for placement inside optical shops and ... statistics, there are over 20,000 optical stores in ... world,s first automated kiosk dedicated to cleaning and sanitizing ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a ... solutions for medical and surgical procedures, among other ... deal with Munich -based Brainlab ... ® Navigation. This agreement applies to the ... cross-disciplinary U.S. sales and all distribution outside the ...
Breaking Medicine Technology:Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
... Pevion Biotech AG today announced ... therapeutic Candida vaccine PEV7, demonstrating the generation of specific ... Furthermore, the results again confirm the capability of Pevion,s ... long-lasting immunity in humans against otherwise weak antigens ...
... Mass. and MIAMI, Jan. 16, 2012 Boston Scientific ... endpoint data from its ORION trial, demonstrating excellent outcomes ... patients with iliac artery disease, a form of peripheral ... insufficient blood flow.  Results were presented today by Daniel ...
Cached Medicine Technology:Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees 2Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees 3Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 2Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 3Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 4Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 5
(Date:9/23/2014)... Angeles, CA (PRWEB) September 23, 2014 ... power score of 3.7 out of 5, indicating ... fixed or portable and range from basic household ... of reading gas concentrations in parts per million. ... them the choice of many suppliers, especially amongst ...
(Date:9/23/2014)... NJ (PRWEB) September 23, 2014 With ... cease the sale of all tobacco products, retail chains ... products and services to patients, customers, and shoppers. In ... the stakeholders of retail pharmacy healthcare to share their ... you need to know to coordinate care with other ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Dallas-based luxury linen ... appointment of Leslie Eades as vice president of product development. ... as well as the primary lead on global sourcing for ... head of both the product development group and sourcing group ... team. , Eades notes, "Peacock Alley is a brand ...
(Date:9/22/2014)... FL (PRWEB) September 23, 2014 ... wrinkles. A Sublime Beauty® cream helps to relax ... boost collagen levels and hydrate beautifully. , "Our ... a multi-tasker for aging skin," says Kathy Heshelow, ... as the natural botox, wrinkles are relaxed while ...
(Date:9/22/2014)... September 23, 2014 Recently, BamboofloorChina.com, an ... new range of solid bamboo floors . According ... are now provided at discounted rates, up to 30 ... until September 30. , BamboofloorChina.com is ... solid bamboo floors are made according to the newest ...
Breaking Medicine News(10 mins):Health News:Gas Detectors Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Gas Detectors Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Retail Pharmacies at the Forefront of Primary Care Innovation 2Health News:Luxury Linen Purveyor Peacock Alley Announces New Vice President of Product Development 2Health News:How to Reduce Wrinkles and Improve Aging Skin from Sublime Beauty®; One Day Sale on Now 2Health News:Cheap Solid Bamboo Floors From Outstanding Online Supplier BamboofloorChina.com 2
... may soon impact the quality of patient care for ... report. ,Without intervention, the number of allergy-immunology ... demand will increase by 35 percent over the next ... ,The decline in the number of qualified allergists-immunologists ...
... today warned consumers could be seriously misled by proposed new ... to Food Standards Australia and New Zealand (FSANZ), Dr Yong ... confuse consumers and may even contribute to unhealthy diets. ... on labels to encourage consumers to buy their products, Dr ...
... insensitive caption for the picture of an abandoned baby in Melbourne ... left in a cardboard box kept by a Japanese hospital for ... Jikei Hospital in the southern city of Kumamoto to discourage abortions ... ,A small hatch on the side of the hospital has ...
... This high degree of trust and confidence in doctors reflects ... survey reflects the immense efforts from doctors to improve ... the financial pressures placed upon the health service. ... this survey, the majority of respondents have answered that doctors ...
... University of Illinois food science and human nutrition professor ... a persons diet , and safe alternatives to hormone-replacement ... spent a decade evaluating the health effects of isoflavones, ... in soy. Much of his work has focused on ...
... of Wisconsin-Madison have designed a powerful analytical tool capable of ... moving proteins in mid-fold and see the shapes of intermediate ... is that the first applications of the technique offer a ... is implicated in type II diabetes. ,Pancreatic ...
Cached Medicine News:Health News:America on Brink of Allergy Crisis 2Health News:Three-year-old Abandoned in Box Meant for Unwanted Babies in Japan 2Health News:Soy Products a Double-edged Sword for Breast Cancer 2Health News:Soy Products a Double-edged Sword for Breast Cancer 3Health News:New Analytical Tool to Unravel the Cause of Diabetes 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: